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Abstract To date there are potential chronology-based but
not conclusive reasons to believe that at least some of the gad-
olinium complexes play a causative role in the pathophysiol-
ogy of nephrogenic systemic fibrosis (NSF) or nephrogenic
fibrosing dermopathy (NFD). Still, the exact pathogenesis
and the risk for patients is unclear beside the obvious con-
nection to moderate to severe renal insufficiency. So far, MR
imaging with Gd-enhancement was regarded as the safest
imaging modality in these patients—the recent development
creates tremendous uncertainty in the MR-community. Nev-
ertheless, one should remember that, despite the over 200
cases of NSF and about 100 with proven involvement of
Gd3+, the vast majority of over 200 million patients exposed
to gadolinium since the 1980s have tolerated these agents
well. Importantly, NSF is a rare disease and does not appear
to occur in patients without renal impairment. Many patients
and researchers have undergone MR investigations with Gd
exposure in the past. For those, it is essential to know about
the safety of the agents at normal renal function. We can
hope that pharmacoepidemiological and preclinical studies
will allow us to better understand the pathophysiology and
role of the various MR contrast agents in the near future.
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Introduction
In the recent years Gd-enhanced MRI has been the accepted
way to go for contrast-enhanced (CE) imaging in patients
with renal insufficiency to avoid the use of iodinated contrast
media (CM) as for CT. For the same patients group, CE-MRA
replaced diagnostic DSA mainly due to its favourable renal
profile and reduced nephrotoxicity. On a molar level there are
little differences between iodinated and gadolinium-contain-
ing agents for what concerns nephrotoxicity, but it is evident
that the dosing is very much in favour of CE-MRA [1–3].
Hypothesis on pathogenesis
Meanwhile, after reviewing the issue of nephrogenic sys-
temic fibrosis (NSF) and on the basis of current evidence,
it seems that some gadolinium-containing contrast agents
may be implicated in its pathogenesis or may even trigger
NSF [4–10]. The suspicion has further been enforced by
the recent detection of gadolinium in tissue biopsy speci-
mens in patients suffering from NSF [11,12]. Thus, the main
hypothesis is that NSF is a rare, chronic disorder following
systemic gadolinium de-chelation causing intoxication with
renal dysfunction at the core of this condition. Released gad-
olinium ions once outside the complex forms hydroxides and
phosphates, which are insoluble at a pH > 6.2 and probably
engulfed by various cells of the mononuclear phagocytic sys-
tem [13]. This might depress the reticuloendothelial system
[14,15], inhibit the activity of certain enzymes with cutane-
ous lesions as consequences [16,17], and cause activation
of foreign body—and of fibrous reactions (in case of NSF
with involvement of dendritic cells, synthesis of TFGβ pre-
cipitating the fibrotic process, attraction of fibrocytes, skin
induration, and mucin production) [10,18].
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Since the recent revision and publication of new guidelines
from various regulatory authorities, suddenly radiologists
and researchers are faced with a radical shift of paradigm—
with drastic measures concerning patients with moderate to
severe renal impairment or a presumed increased nephrotoxic
risk (GFR < 30 ml/min per 1.73 m2) [19–22]. The goal of this
editorial review is to sensitise healthcare professionals about
NSF and the new security guidelines, which also imply differ-
ences between the clinically used gadolinium agents and to
discuss shortly the following related questions:
(a) How do we deal with the new regulations for clinical
routine MRI and which alternatives exist for patients
with renal impairment?
(b) How could it come, that such a distinct and severe dis-
order was only recognised after more than 200 cases
worldwide and after such a long time delay?
(c) How can we impede similar safety risks in the future?
(d) What are the consequences besides clinical routine for
research and ongoing clinical studies?
Gd-compounds and transmetallisation
As most of the cases were only discovered in 2006 following
the first warnings of experts such as Grobner or Thomsen [4,
6,23], there are still differences between the single national
or international guidelines (FDA/EMEA). So far, over 90%
of all NSF cases occurred after gadodiamide (Omniscan)
explaining the more severe contraindications and reluctance
for this agent. Single cases have been reported in the USA
and Europe after gadopentetate dimeglumine (Magnevist)
and gadoversetamide (Optimark), which both form linear
complexes. Macrocyclic agents such as gadoteridol (Pro-
hance), gadobutrol (Gadovist) or gadoterate meglumine
(Dotarem) are slightly more stable than linear complexes
because the Gd3+ is caged in a cavity. Linear compounds
exhibit more toxic effects after repeated administrations than
cyclic compounds, particularly on the reproductive functions
and the skin [17,24,25] (Fig. 1).
Further on, a high number of ionic bonds between the
ligand and gadolinium increase the stability of the chelates.
Therefore, the dynamic process of gadolinium release dif-
fers from one chelate to another (dissociation kinetic rate
e.g., at low pH; Table 1). Actually, there is always a balance
between the free ligand and gadolinium and the complex-
bound form, with in general a pronounced over-balance to the
right [26–28]:
Gd3+ + ligand(free)  Gd-chelates (complex) (1)
To minimize the risk of release of free gadolinium or in order
to shift more towards the right, manufacturers have often
added additional, excess or free chelate in their pharmaceu-
tical preparations [10].
Importantly, the elimination half-life of these agents is
prolonged 20-fold and more (34.2 h for gadodiamide) in case
of terminal renal insufficiency up from a normal 1.5 h in
healthy subjects [29–33]. The delayed excretion of the con-
trast agent in patients with renal impairment dramatically
increases the contact time with the body and thus enhances
the risk of biological reactions. The different conditional sta-
bilities and dynamics affect their behaviour in the body and
might lead to a release of free (toxic) gadolinium. Moreover,
transmetallisation which occurs more likely in case of unsta-
ble complexes or in case of prolonged interaction with endog-
enous ions might be explained by contestation of the binding
sites of gadolinium [34–41,45]. Probably, in case of dialy-
sis and accompanied treatment an increased number of free
Fig. 1 Structural formulas of
gadolinium (III) complexes.
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electrolytes together with the delayed elimination of the gad-
olinium contrast agent promote such liberation. Ultimately,
this may favour the occurrence of toxic manifestations for
compounds with poorer stability—but this has not yet been
proven clinically for NSF:
Equation for transmetallisation:
Metaln+(free)+Gd-complexMe-complex+Gd3+(free)
(2)
Guidelines
In Europe the CHMP (Committee for Medicinal Products for
Human Use) has issued on 7 Feb 2007 the following warn-
ing which should be implemented rapidly in each country
[20–22]:
For gadodi ami de (Omni scan) :
Gadodiamide is contraindicated in patients with severe renal impair-
ment (GFR < 30 ml/min per 1.73 m2), and those who have had or are
undergoing liver transplantation
Special warnings and precautions for use:
Severe renal impairment and liver transplant patients:
There have been reports of nephrogenic systemic fibrosis (NSF)
associated with use of gadodiamide and some other gadolinium-
containing contrast agents in patients with severe renal impairment
(GFR< 30 ml/min per 1.73 m2) and those who have had or are undergo-
ing liver transplantation. Therefore Omniscan should not be used in
these populations.
Neonates and infants:
Due to immature kidney function in neonates and infants up to 1 year
of age, Omniscan should only be used in these patients after careful
consideration.
Undesirable effects:
Cases of NSF have been reported with Omniscan .
All other gadol inium − containing cont rast agents should
add st rong warnings about potent i al N SF wi th the
f ol lowing proposed SPC wording :
Special warnings and precautions for use:
There have been reports of NSF associated with use of some gadolin-
ium-containing contrast agents in patients with severe renal impairment
(GFR < 30 ml/min per 1.73 m2). As there is a possibility that NSF may
occur with XXX, it should only be used in these patients after careful
consideration.
The most recent knowledge must be taken into account,
forcing us to be aware of the revised national and international
guidelines concerning renal insufficiency, which might vary
from one country to another! Among others, most national
and international Radiological and MR—Societies provide
the respective LINKs on their homepage [46–49].
(a) How do we deal with the new guidelines in clinical
routine MRI and what are the alternatives?
Especially, the population with an eGFR (estimated GFR) <
30 ml/min per 1.73 m2) that shall be protected by the new
guidelines will also potentially suffer the most from this
regulation. It is important to underline the fact, that most
gadolinium complexes may still be used in case of terminal
renal insufficiency, but the risk/benefit ratios must directly
be compared to the application of CT with iodinated CM.
More stable Gd complexes should be preferred. The stan-
dard Gd CM dose of 15–20 ml for an adult corresponding to
0.1 mmol/kg body-weight contains only about 7.5–10 mmol
(=0.0075-0.01 mol), while 100 ml of a iodinated contrast
agent correspond to almost 0.1 mol of active substance (for
monomeric non-ionic CM). Nephrotoxicity is directly related
to the applied dose in mole [2,3]. Despite this evident advan-
tage for CE-MRI vs CE-CT, indication and renal function
must be assessed. If necessary, renal protection must be care-
fully ensured. The following practical recommendations
might help [7,10,22]:
1. Definition of serum creatinine (SCr) (not older than
2 weeks) and calculation of eGFR for
(a) patients bearing an increased nephrotoxic risk (see
below)
(b) all patients with a history of chemotherapy, blood
or connective tissue disorder or a “pro-inflamma-
tory” disease (major surgery, vasculitis, thrombosis,
systemic infection, liver cirrhosis, acidosis) within
6 months prior to the examination.
2. Assessment of further renal risk factors such as advanced
age (>70 years), suspected or known renal diseases, dia-
betes mellitus, arteriosclerosis or peripheral vascular dis-
ease, congestive cardiac failure, nephrotoxic medication
(contrast load in the previous 72 h, diuretics, NSAID,
aminoglycosides, amphotericin, cyclosporine A), hyper-
uricemia, history of dialysis.
In case of eGFR < 30 ml/min per 1.73 m2 one should be reluc-
tant to use gadolinium, prefer more stable gadolinium com-
plexes and limit the contrast application to single dose
(0.1 mMol/kg bw). Repeated dosing within a time frame of
1 week should be avoided. Hemodialysis does not necessarily
protect from the appearance of NSF, and therefore is not gen-
erally recommended after the administration of gadolinium
agents [10,43].
Gd should be avoided if ever possible in case of the fol-
lowing:
1. Known allergies to any gadolinium contrast agent.
2. Known or diagnosed NSF
During and after the examination, a standardized scheme of
hydration might help to prevent nephrotoxicity and eventual
accumulation of Gd (no evidence yet).
Finally, it cannot be recommended as alternative to Gd-
enhanced MRI, to perform CE-CT in patients with severe
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Table 1 Stability constants of all marketed Gd3+ chelates in order of stability [27,28,34,42]
Contrast agent Trade name Chemical structure log Ktherm log K ′ T 1/2 in 0.1N HCl [34,42]
Gd-DTPA-BMA Omniscan Linear, non-ionic 16.9 14.9 35s
Gd-DTPA-BMEA OptiMARK Linear, non-ionic 16.6 15.0
Gd-BOPTA MultiHance Linear, di-ionic 22.6 16.9
Gd-DTPA Magnevist Linear, di-ionic 22.1 17.7 10 min
Gd-EOB-DTPA Primovist Linear, di-ionic 23.5 N/A
Gd-BT-DO3A Gadovist Macrocyclic, non-ionic 21.8 N/A
Gd-HP-DO3A ProHance Macrocyclic, nonionic 23.8 17.1 3 h
Gd-DOTA Dotarem Macrocyclic, ionic 25.8 18.8 >1 month
NA Not available; log Ktherm thermodynamic stability constant; log K ′ conditional stability constant at a pH of 7.4
renal insufficiency (if not under dialysis). Non-enhanced MRI
or other non-contrast imaging modalities are the methods of
choice.
(b) How could it come that such a distinct and severe
disorder was only recognised after more than 200 cases
worldwide and after such a long time delay?
High doses of Gd agents are mostly applied for indications
such as MRA—and the majority of NSF cases occurred espe-
cially after high dose MRA. It is interesting to note that the
onset of first reported NSF in 1997 [8] coincides closely
with the success of CE-MRA. Actually, in the middle of the
1990s, suddenly CE-MRA allowed not only to diagnose and
overlook much more rapidly the vascular situation, but addi-
tionally promised to reduce nephrotoxicity—even with triple
dose Gd applied [44]. The literature shows only very few clin-
ical studies addressing more in depth the security question in
case of terminal renal insufficiency [3,30–33]. Mostly they
limit the patient follow-up to 72 h, mainly renal endpoints
were assessed and only the acute phase was followed. No
prolonged studies were performed as it was assumed that
these diagnostic agents were injected only once—without
taking into consideration the wide extension of indications,
increased use also in case of follow-up studies (multiple scle-
rosis, oncology, CE-MRA) or the delayed elimination rate in
case of renal insufficiency.
Underreporting of chronic or long-term effects is a well
known reality—not only valid for gadolinium agents, but also
in general for all drugs. Still nowadays few data are available
about the incidence of thyroid reactions after iodinated agents
or about type IV hypersensitivity reactions after gadolinium
agents. Also renal insufficiency following the non-specific
gadolinium complexes is rarely reported and so on.
Besides demanding for more clinical studies with clearly
defined risk-groups the radiologic community should also
be aware of its own responsibility regarding the reporting of
adverse events. The overarching aim must be to gain more
data about adverse effects observed after the patient has left
the imaging department in narrow conjunction with clini-
cians. Clear documentation on all contrast procedures as well
as on the type of contrast agent must be available for the cli-
nicians at any time.
(c) How can we impede similar safety risks in the future?
As has been said previously it is primarily a matter of sensiti-
sation of all involved partners, the clinicians, the radiologists,
the pharmaceutical companies and also the health authorities.
As in case of previous safety risks with drugs, it became evi-
dent that apparently there was uncertainty if not lacking data
about the population with terminal renal insufficiency. Radi-
ologists, despite the evident shift of clinical use, must remain
prudent in such cases. More prospective clinical data must
be acquired and published to justify the use of just any agent
in case of pronounced risk.
Secondly, as soon as a possible risk is recognized, health
authorities and responsible pharmaceutical companies must
inform others around the world. In the present case one must
also ask why warnings were so different from one country
to another. As soon as the higher risk associated with gad-
odiamide was evident, which seemed to be the case already
in July 2006, a general warning to healthcare professionals
would have been opportune. Transparency of information is
a key-issue as we all have rapid access to online informa-
tion and should be used just to avoid any single unnecessary
patient risk.
(d) What are the consequences besides clinical routine for
research and ongoing clinical studies?
All ongoing clinical studies with gadolinium agents must be
carefully checked and must comply as well with those or
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similar guidelines proposed by the authorities. An excep-
tion might be research studies deliberately following the
NSF issue or renal tolerance. But even in these cases, ethical
considerations with a thorough risk/benefit analysis must be
taken into account, thus leading at least to a modification of
informed consent. Ongoing studies must be adapted instan-
taneously after informing the ethical committees about this
issue.
Clearly, as there remains much uncertainty, new studies
addressing the various questions about NSF should be per-
formed.
Conclusion
Compliance with the new extended directives by authorities
such as EMEA and FDA on the application of Gd complexes
in patients with known renal impairment must be assured.
Radiologists must familiarise themselves with the calcula-
tion of eGFR and the risk of NFS in renal insufficiency. Nev-
ertheless, it is important to underline, that gadolinium agents
remain one of the safest drug groups and, last but not least,
are less nephrotoxic than iodinated agents on a volume level.
We must be aware, that this is not a problem of one single
drug, but statistically it is just a matter of time to notify NSF
incidents for all Gd compounds. In practice, careful anam-
nesis to retrieve cases of terminal renal impairment is man-
datory to avoid NSF.
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